Madrigal Pharmaceuticals, Inc. (MDGL) Research

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.

Market snapshot

Symbol
MDGL
Price
$505.75
Day change
+1.18%
Market cap
$11.7B
P/E ratio
-47.45x
52-week range
276.67-615
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$656

Peer companies

  • Abivax S.A. (ABVX)
  • Baxter International Inc. (BAX)
  • BioMarin Pharmaceutical Inc. (BMRN)
  • Caris Life Sciences, Inc. (CAI)
  • Exelixis, Inc. (EXEL)
  • Jazz Pharmaceuticals plc (JAZZ)
  • Moderna, Inc. (MRNA)
  • Atrium Therapeutics, Inc. (RNA)

Recent insider activity

  • Taub Rebecca — A-Award (454 shares) on 2026-06-17
  • Taub Rebecca — A-Award (766 shares) on 2026-06-17
  • Levy Richard S — A-Award (454 shares) on 2026-06-17
  • Levy Richard S — A-Award (766 shares) on 2026-06-17
  • FOUSE JACQUALYN A — A-Award (454 shares) on 2026-06-17

Open Madrigal Pharmaceuticals, Inc. (MDGL) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.